Post-marketing surveillance for refractory uveoretinitis associated with Behcet's disease under Remicade treatment

Post-marketing surveillance for refractory uveoretinitis associated with Behcet's disease under Remicade treatment - PMS of Remicade for refractory uveoretinitis associated with Behcet's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027733

Enrollment

100

Registered

2017-06-12

Start date

2007-01-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behcet&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with refractory uveoretinitis associated with Behcet's disease who use Remicade (Limited to those having inadequate response to conventional therapy)

Exclusion criteria

Exclusion criteria: Patients who meet "CONTRAINDICATIONS" to the use of Remicade

Design outcomes

Primary

Measure	Time frame
Incidence of adverse drug reactions, and efficacies (physician global assessment, incidence of ocular attacks, and corrected visual acuity)	—

Secondary

Measure	Time frame
Correlation factors of the safety and efficacy	—

Countries

Japan

Contacts

Public ContactToshiro Yano

Tanabe Pharma Corporation Ikuyaku. Integrated Value Development Division, Medical Affairs I Department

yano.toshiro@mc.mt-pharma.co.jp06-6205-5614

Outcome results